• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

INFIGRATINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • INFIGRATINIB chembl:CHEMBL1852688 Antineoplastic

    Alternate Names:

    BGJ398
    NVP-BGJ398
    BGJ-398
    INFIGRATINIB
    MVP-BGJ398
    chembl:CHEMBL1852688
    chemidplus:872511-34-7
    drugbank:11886
    pubchem.compound:53235510

    Drug Info:

    Pharmaceutical Developer Novartis
    Source Reported Drug Name(s) BGJ398
    Drug Class Pan-FGFR Inhibitor
    Notes dual PI3K/mTOR inhibitor
    Drug Class Kinase Inhibitors
    (6 More Sources)

    Publications:

    Martignetti et al., 2014, Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA., Neoplasia
    Konecny et al., 2013, Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells., Mol. Cancer Ther.
    Packer et al., 2017, PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers., Mol. Cancer Ther.
    Tanizaki et al., 2015, Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2., Cancer Res.
    Arai et al., 2014, Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma., Hepatology
    Künstlinger et al., 2015, FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro., Oncotarget
    Liu et al., 2017, c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors., Clin. Cancer Res.
    Goyal et al., 2017, Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma., Cancer Discov
    Nogova et al., 2017, Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study., J. Clin. Oncol.
    Javle M et al., 2018, Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma., J Clin Oncol
    Singh et al., 2012, Transforming fusions of FGFR and TACC genes in human glioblastoma., Science
    Göke et al., 2015, FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers., Clin. Cancer Res.
    Chudasama et al., 2017, Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma., Clin. Cancer Res.
    Manchado et al., 2016, A combinatorial strategy for treating KRAS-mutant lung cancer., Nature
    Pal SK et al., 2018, Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations., Cancer Discov
    Guagnano et al., 2012, FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor., Cancer Discov
    Nakanishi et al., 2015, Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1., Mol. Cancer Ther.
    Capelletti et al., 2014, Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma., Clin. Cancer Res.
    von Mässenhausen et al., 2016, Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma., Target Oncol
    Pan et al., 2015, Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy., PLoS ONE
    Chandrani et al., 2017, Drug-sensitive FGFR3 mutations in lung adenocarcinoma., Ann. Oncol.
    Li et al., 2015, FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors., Cancer Discov
  • INFIGRATINIB   FGFR2

    Interaction Score: 0.99

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Direct Interaction yes
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor

    PMIDs:
    24563622 23443805 28119489 26048680 24122810 26036639 27401245 28034880 27870574 29182496


    Sources:
    TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial OncoKB

  • INFIGRATINIB   FGFR3

    Interaction Score: 0.86

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    29848605 27870574 27401245 23002168 25589496 25294908 22837387 27053219 28034880 26270481 27998968


    Sources:
    TALC MyCancerGenome JAX-CKB ChemblInteractions CIViC CancerCommons MyCancerGenomeClinicalTrial OncoKB

  • INFIGRATINIB   FGFR1

    Interaction Score: 0.43

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Notes
    Indication/Tumor Type uterus leiomyosarcoma

    PMIDs:
    22837387 27870574 26015511 27535980


    Sources:
    CancerCommons MyCancerGenomeClinicalTrial OncoKB TTD TALC JAX-CKB MyCancerGenome ChemblInteractions CIViC

  • INFIGRATINIB   FGFR4

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Mechanism of Interaction Fibroblast growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions CancerCommons

  • INFIGRATINIB   PIK3C3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   PIK3C2A

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   PIK3C2B

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   PIK3C2G

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   PIK3R6

    Interaction Score: 0.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   PIK3R4

    Interaction Score: 0.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   KIT

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BGJ398 + Imatinib
    Indication/Tumor Type gastrointestinal stromal tumor
    Response Type sensitive

    PMIDs:
    25673643


    Sources:
    JAX-CKB

  • INFIGRATINIB   PIK3R3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   PIK3R5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   PIK3R1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   PIK3R2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   PIK3CD

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   PIK3CA

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy BGJ398 + BKM120
    combination therapy BGJ398 + BYL719
    Evidence Type Actionable

    PMIDs:
    28119489


    Sources:
    MyCancerGenome JAX-CKB

  • INFIGRATINIB   PTEN

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BGJ398 + BYL719
    Indication/Tumor Type endometrial cancer
    Response Type sensitive

    PMIDs:
    28119489


    Sources:
    JAX-CKB

  • INFIGRATINIB   PIK3CB

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   KRAS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    27338794


    Sources:
    JAX-CKB

  • INFIGRATINIB   PIK3CG

    Interaction Score: 0.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • INFIGRATINIB   MTOR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • CancerCommons: BGJ398

    • Version: 25-July-2013

    Alternate Names:
    BGJ398 PubChem Drug Name
    53235510 PubChem Drug ID
    BGJ398 Drug Trade Name

    Drug Info:
    Drug Class Pan-FGFR Inhibitor
    Source Reported Drug Name(s) BGJ398
    Pharmaceutical Developer Novartis

    Publications:

  • MyCancerGenome: BGJ398

    • Version: 20-Jun-2017

    Alternate Names:
    BGJ398 Development Name
    NVP-BGJ398 Development Name
    BGT226 Development Name

    Drug Info:
    Drug Class Kinase Inhibitors
    Notes dual PI3K/mTOR inhibitor

    Publications:

  • JAX-CKB: BGJ398

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Liu et al., 2017, c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors., Clin. Cancer Res.
    Konecny et al., 2013, Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells., Mol. Cancer Ther.
    Arai et al., 2014, Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma., Hepatology

  • CIViC: INFIGRATINIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Chandrani et al., 2017, Drug-sensitive FGFR3 mutations in lung adenocarcinoma., Ann. Oncol.
    Pal SK et al., 2018, Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations., Cancer Discov
    Nogova et al., 2017, Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study., J. Clin. Oncol.

  • TTD: BGJ398

    • Version: 2020.06.01

    Alternate Names:
    D03LWG TTD Drug ID

    Drug Info:

    Publications:

  • TALC: BGJ398

    • Version: 12-May-2016

    Alternate Names:
    BGJ398 Primary Drug Name
    BGJ398 Drug Synonym

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1852688

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: BGJ398

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: BGJ398

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1852688

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21